Table 2.
Summary of small molecules in phase 3 clinical trials.
| Small Molecules | |||
|---|---|---|---|
| Hydralazine hydrocloride | Free radical scavenger | NCT04842552 | December 2023 |
| Icosapent ethyl | Purified form of the omega-3 fatty acid eicosapentaenoic acid | NCT02719327 | September 2023 |
| Metformin | Insulin sensitizer | NTC04098666 | April 2026 |
| AGB101 | Anti-seizure medicament | NCT03486938 | November 2022, Ended |
| Blarcamesine (ANAVEX 2-73) |
Mixed ligand of the sigma-1 receptor (σ1R) and the M2 muscarinic receptor | NCT04314934 | July 2024 |
| Fosfogonimenton (ATH-1017, NDX-1017) |
HGF/MET system | NCT04488419 | February 2024 |
| Masitinib | Tyrosine kinase inhibitor | NCT05564169 | December 2025 |
| NE3107 | Derivative of β-androstenetriol | NCT04669028 | October 2023 |
| Nilotinib | c-Abl tyrosine kinase inhibitor | NCT05143528 | June 2026 |
| Piromelatine | Agonist of melatonin and serotonin receptors | NCT05267535 | June 2025 |
| Simufilam | Inhibitor of scaffold protein Filamin A | NCT05575076 | July 2027 |
| Valiltramiprosate (ALZ-801) |
Prevents neurotoxic Aβ formation with no plaque interaction | NCT04770220 | June 2024 |
| Hydromethylthionine mesylate | Tau aggregation inhibitor | NCT03446001 | Completed |